Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new Northwestern Medicine multi-site study.
In the near future, patients won’t have to waste time and be disappointed with months of ineffective therapy, scientists said.
“Now we can start to predict which drugs a patient will respond to,” said co-senior author Harris Perlman, chief of rheumatology at Northwestern University Feinberg School of Medicine. “We can truly do precision medicine for rheumatoid arthritis. I believe this could be game changing. ”
The paper was recently published as an uncorrected proof in Arthritis & Rheumatology and will be officially published in the journal in late May. Richard Pope and Deborah Winter also are lead Northwestern authors.
Treatment for rheumatoid arthritis now is trial and error.
“We have so many different biologic drugs and there’s no rhyme or reason to give one drug versus the other,” Perlman said. “We waste $2.5 billion a year in ineffective therapy. And patients go through 12 weeks of therapy, don’t respond and get upset.”
Scientists in the multi-site study were the first in the U.S. to use ultrasound-guided therapy to take a tissue biopsy in the affected joint. In the past, blood samples were used to try to determine the effectiveness of the therapy and disease progression.
“It’s just like oncology, where you go to the tumor,” Perlman said. “Why go anywhere else? In rheumatoid arthritis, we’ve never gone to the target organ.”
Improved ultrasound guided techniques make the new technique possible, Perlman said, noting joint biopsies began in Europe about six years ago.
Scientists in the six-site study analyzed the tissue in 41 rheumatoid arthritis patients, separating out different immune cell populations. They focused on macrophages, essentially the garbage collectors of the immune system that are overactive in rheumatoid arthritis. These cells produce toxic, inflammatory proteins that destroy the joints. Biologic therapy removes the protein molecules being secreted by the macrophages.
The study included 30 patients from Northwestern and the remaining 11 from the University of Alabama at Birmingham; Washington University, Columbia University, Mayo Clinic and University of Michigan.
In the past, scientists have tried to determine therapeutic effectiveness by separating patients into groups based on their clinical parameters such as what antibodies they are producing against themselves, how swollen their joints are and medications they are taking. Then scientists tried to see if these parameters could predict therapeutic efficacy. But that hasn’t worked, Perlman said.
Instead, Perlman and colleagues segregated patients based on the genes being produced by their macrophages. They identified two patient groups who shared aspects of the genetic profiles.
Next, the scientists identified which of these patient populations had joints that were getting better and what biologic therapies they were taking. They also identified a gene sequence associated in patients with early disease. The earlier the patient is treated, the more effective the therapy.
The next goal is to predict which patients will have the best response — based on their genetic signature — to a specific drug.
In a new study, researchers are taking joint biopsy tissue from patients at the start of a new therapy and then six weeks later to see if they can find a predictor gene sequence that will clearly identify which patients respond to a particular therapy.
“The idea is to develop gene sequences to predict whether a patient will respond or not,” Perlman said. “Our goal is that this procedure will become the standard of care of for all patients with rheumatoid arthritis.”
Learn more: Rheumatoid arthritis meets precision medicine
The Latest on: Rheumatoid arthritis
via Google News
The Latest on: Rheumatoid arthritis
- AbbVie’s Successor to Humira Wins FDA OK for Rheumatoid Arthritison August 16, 2019 at 3:29 pm
An anti-inflammatory drug that AbbVie has been developing as a successor to adalimumab (Humira), the world’s top-selling drug, won the regulatory OK Friday as a treatment for rheumatoid ...
- FDA approves Humira maker AbbVie's new rheumatoid arthritis drugon August 16, 2019 at 3:23 pm
The drug, Rinvoq, belongs to a class of drugs known as JAK inhibitors that block inflammation-causing enzymes called Janus kinases. It is set to compete with Pfizer's Xeljanz and Eli Lilly's Olumiant.
- AbbVie prices new rheumatoid arthritis drug at $59,000 a yearon August 16, 2019 at 1:58 pm
(Reuters) - AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition ...
- Another 'Jakinib' OK'd for Rheumatoid Arthritison August 16, 2019 at 12:47 pm
Another so-called JAK inhibitor, upadacitinib (Rinvoq), won FDA approval for treating rheumatoid arthritis, manufacturer AbbVie announced Friday. The oral drug is indicated for patients with ...
- AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritison August 16, 2019 at 10:00 am
- RINVOQ (upadacitinib) met all primary and ranked secondary endpoints across a variety of patients with moderately to severely active rheumatoid arthritis[1-7] - Durable remission rates with ...
- FDA approves AbbVie's new rheumatoid arthritis drugon August 16, 2019 at 9:43 am
(Reuters) - The U.S. Food and Drug Administration on Friday approved AbbVie Inc’s new treatment for rheumatoid arthritis, a win for the drugmaker seeking to widen its portfolio as its blockbuster ...
- EMA accepts Gilead's filgotinib application for rheumatoid arthritison August 15, 2019 at 6:17 pm
Gilead Sciences (GILD-0.4%) and collaboration partner Galapagos NV (GLPG) announce that the European Medicines Agency (EMA) has accepted for review their marketing application for JAK1 inhibitor ...
- EUROPEAN MEDICINES AGENCY VALIDATES MARKETING APPLICATION FOR FILGOTINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITISon August 15, 2019 at 1:01 pm
Aug 15, 2019 (GLOBE NEWSWIRE via COMTEX) -- Foster City, Calif. and Mechelen, Belgium - August 15, 2019 22.01 CET - Gilead Sciences, Inc. GILD, -0.40% and Galapagos NV (euronext & nasdaq:GLPG) today ...
- Rheumatoid arthritis may start in the lungs rather than jointson August 15, 2019 at 5:02 am
ORLANDO — A line of progression from disease susceptibility to overt rheumatoid arthritis could potentially begin with environmental factors in the lungs, as well as the gingiva, according to a ...
via Bing News